Thyrocare's Q1 Profit Rises 34% to ₹51 Cr
PharmEasy-owned diagnostics company Thyrocare reported a 34% increase in its first-quarter profit, reaching ₹51.3 crore. Revenue from operations also saw a 24.4% jump.
Thyrocare, a diagnostics company owned by PharmEasy, announced its first-quarter financial results for the period ending June 30, 2026 (Q1 FY27), with a consolidated net profit of ₹51.3 crore. This represents a 34% increase compared to the ₹38.3 crore profit recorded in the same quarter of the previous year. Sequentially, the profit grew by 5.3%.
The company's revenue from operations for the quarter surged by 24.4% to ₹240 crore, up from ₹193 crore in the first quarter of FY26. On a quarter-over-quarter basis, revenue saw a rise of just over 7%.
Total expenses for Thyrocare during the same period increased by 19.8%, amounting to ₹176.6 crore, compared to ₹147.5 crore in the prior year's first quarter.